Enzymatica AB: Enzymatica's Nomination Committee for the Annual General Meeting 2018 appointed

Pressrelease
Lund 29 November 2017

Enzymatica's Nomination Committee for the Annual General Meeting 2018 appointed

In accordance with the principles for the Nomination Committee established at the Annual General Meeting 2016, the Nomination Committee for the next Annual General Meeting shall consist of representatives of the four largest shareholders registered in the register of shareholders held by Euroclear Sweden AB as of 31 October each year, together with the Chairman of the Board, who shall also convene the Nomination Committee until its first meeting.

The four largest owners (appointed representative in the nomination committee in brackets) as of 31 October 2017 were Abanico Invest AB (Håkan Roos), Protenus Ltd (Gudmundur Palmason), Gadice ehf. (Ágústa Gudmundsdottir) and Roosgruppen AB (Björn Algkvist), who together with the chairman of the board, Bengt Baron, constitute the nomination committee for the 2018 Annual General Meeting. Håkan Roos has been appointed Chairman of the Nomination Committee.

The Nomination Committee's task is to submit to the Annual General Meeting proposals for chairman and other members of the Board, as well as fees and other remuneration for board assignments to each of the Board members. The Nomination Committee shall also submit proposals for election and remuneration of the auditor.

Shareholders who wish to submit proposals to the Nomination Committee can do this by email at the latest on 8 March 2018 to: louise.forssell@enzymatica.com

For more information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB
Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com   

About Enzymatica AB

Enzymatica AB is a life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company's first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in around ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information please visit: www.enzymatica.se. 

Enzymatica's Certified Adviser is Erik Penser Bank.